Halozyme Therapeutics Inc (HALO)
47.00
+0.06
(+0.14%)
USD |
NASDAQ |
Dec 23, 13:44
Halozyme Therapeutics Cash from Investing (Quarterly): -167.48M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Lexicon Pharmaceuticals Inc | 53.47M |
| Novavax Inc | 31.91M |
| Kura Oncology Inc | 45.54M |
| TransMedics Group Inc | -47.76M |
| Pulmonx Corp | 6.751M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 115.38M |
| Cash from Financing (Quarterly) | 18.56M |
| Free Cash Flow | 392.71M |
| Free Cash Flow Per Share (Quarterly) | 0.8749 |
| Free Cash Flow to Equity (Quarterly) | 112.22M |
| Free Cash Flow to Firm (Quarterly) | 117.61M |
| Free Cash Flow Yield | 6.44% |